Atezolizumab and bevacizumab before liver transplant for liver cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests giving atezolizumab plus bevacizumab before liver transplant in people with hepatocellular carcinoma (HCC) that is too advanced to be listed within the “Milan criteria,” but still transplant-eligible. The goal is to control the cancer outside the transplant period and improve transplant outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re age 18 or older, and you can sign consent.
- You have confirmed liver cancer (HCC) that can be measured, or can be assessed, and it is not spread outside the liver.
- A liver transplant is an option for you, and your doctors also consider you able to receive TACE treatment.
- Your liver function is good enough (Child-Pugh score A6 or less).
- Your performance status is good (ECOG 0–1), and you can reasonably expect to live at least 6 months.
- Your blood counts and organ function meet lab limits, and you have been checked recently (within 14 days).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs (atezolizumab and bevacizumab) plus a targeted radiation treatment (Y-90 radioembolization) for people with liver cancer who are waiting for a liver transplant. The goal is to see if this treatment can help control the cancer and improve transplant outcomes.
This trial studies whether a combination of immune therapy (atezolizumab) and a blood-vessel-targeting drug (bevacizumab) works better than a standard procedure called TACE for people with intermediate-stage liver cancer (HCC). It may help shrink tumors and help patients live longer with fewer complications.
This trial tests a combination of three treatments—two immunotherapy/anti-cancer drugs (bevacizumab and atezolizumab) plus a catheter-based liver treatment (TACE-HAIC)—for people with unresectable hepatocellular carcinoma (liver cancer that cannot be surgically removed). The goal is to slow or shrink the cancer.
This trial tests adding two immunotherapy and anti-angiogenesis drugs (atezolizumab and bevacizumab) to standard photon radiation for people with liver cancer that cannot be surgically removed. It aims to see if this combination can shrink tumors and improve outcomes.
This Phase 2 trial tests whether atezolizumab plus bevacizumab, given along with liver cancer treatment procedures (TACE/HAIC), can help people with advanced liver cancer that cannot be removed by surgery. It mainly looks at whether these medicines can control the cancer more effectively and safely.
This trial tests a combination of two immunotherapy drugs (atezolizumab and bevacizumab) with or without targeted radiation therapy for liver cancer that has invaded the major blood vessels of the liver. The goal is to see if adding radiation helps shrink tumors or slow the disease.
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.